TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · no major macro event
ACRS

Aclaris Therapeutics Inc

Healthcare · Biotechnology

4.30$ -2.7% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

Aclaris Therapeutics Inc (ACRS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 180 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios
Annual Quarterly
Amounts Change % Common size %
Last 12 Full history
Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ACRS
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
86 176 166 177 261 244 221 202 176 276 253 217 160 98 97 85 72 71 161 288 263 251 227 278 268 255 230 236 218 197 174 161 182 220 198 189 176 160 199 180
86 174 157 176 234 209 192 171 146 179 157 138 145 84 83 71 58 57 135 241 206 205 191 259 257 232 184 133 123 129 135 118 132 126 109 104 101 151 110 98
18 30 24 33 60 209 55 46 27 57 34 32 30 36 54 33 24 22 35 113 54 27 36 68 62 45 45 31 39 40 36 23 48 25 30 25 25 20 29 19
84 174 153 170 228 209 187 165 134 168 137 116 91 75 79 68 53 54 128 232 198 191 180 249 248 218 171 120 103 119 128 111 128 114 105 100 96 91 105 92
0.0 0.0 0.0 0.0 0.7 0.5 0.5 2.2 1.0 4.9 16 19 0.7 0.7 0.9 0.8 0.9 0.8 0.8 0.9 0.8 0.6 0.6 0.6 0.6 0.5 0.7 0.4 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.2 4.7 5.6 4.8 6.2
0.0 0.0 0.0 0.0 0.0 -6.4 0.0 1.0 1.0 0.8 0.9 0.2 51 5.0 – 0.0 0.0 – 0.0 0.0 – -34 0.0 – – -12 -34 -91 -84 – 0.0 – – – – – – – – –
0.5 0.5 0.7 0.9 1.2 2.2 2.2 4.4 4.4 4.3 4.0 9.3 7.7 7.2 6.8 6.7 1.9 1.7 1.4 5.1 1.2 1.3 1.3 1.3 1.1 1.1 1.5 1.9 4.3 – – – – – – – – – – –
0.0 0.0 0.0 0.0 19 19 19 19 19 19 19 0.0 0.0 0.0 – – – – – – – – – – – – – – – – – – – – – – – – – –
0.0 0.0 0.0 0.0 7.4 7.3 7.3 7.3 7.3 73 71 70 7.2 7.2 7.2 7.2 7.1 7.1 7.1 7.1 7.1 7.0 7.0 7.0 7.0 7.0 7.0 6.9 6.9 0.3 – – – – – – – – – –
4.9 6.6 5.9 8.7 17 18 20 28 30 60 71 80 75 28 39 36 31 33 49 54 47 54 46 42 48 57 53 56 62 40 32 27 52 65 54 57 55 57 55 55
4.6 6.2 5.6 8.4 10.0 13 14 20 22 27 36 43 39 22 21 18 13 15 15 15 18 23 17 16 20 22 18 23 27 31 20 16 19 32 22 27 26 29 27 28
– – – – – 0.1 0.1 0.6 0.6 0.1 0.9 1.0 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.7 0.7 0.7 0.7 0.8 0.7 0.6 0.5 0.3 0.4 0.5 0.4 0.5 0.5 0.5 0.5 0.5 0.6 0.6 –
1.8 2.8 3.6 5.8 6.5 7.8 8.1 13 14 12 15 14 18 9.9 6.9 5.5 5.1 5.3 7.3 4.2 7.6 10.0 8.1 5.7 7.7 10 8.2 11 9.6 8.9 11 7.3 7.7 4.7 6.4 8.8 9.2 13 15 16
0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 30 30 30 30 – 11 11 11 11 11 11 – – – – – – – – – – – – – – – – – – – –
81 169 160 168 244 225 200 174 146 215 182 137 85 70 58 49 41 38 112 234 217 197 180 236 220 198 177 180 156 157 142 134 130 156 144 132 120 103 144 125
-79 -91 -103 -118 -137 -159 -190 -221 -254 -292 -330 -380 -435 -454 -469 -481 -491 -505 -533 -551 -573 -595 -614 -635 -655 -682 -710 -740 -769 -771 -788 -799 -806 -903 -918 -933 -948 -968 -988 -1,009
21 23 26 27 29 31 31 31 31 39 41 41 41 41 42 42 43 43 50 54 61 61 61 66 67 67 67 71 71 71 71 71 71 95 122 123 123 123 129 143

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?